Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis, Hematology |
| Therapuetic Areas: | Hematology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
| End Date: | August 2012 |
An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)
The purpose of this study is to test the safety and tolerability of eltrombopag when used to
increase and maintain platelet count. Platelet count to be maintained at a level sufficient
to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose
reductions, and to avoid permanent discontinuation of antiviral therapy.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
1 Medical Center Drive
Morgantown, West Virginia 26506
Morgantown, West Virginia 26506
304-598-4800
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
Click here to add this to my saved trials
Click here to add this to my saved trials